about
Ribonucleases as novel chemotherapeutics : the ranpirnase exampleReversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides.Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection.In vivo delivery of cell-permeable antisense hypoxia-inducible factor 1α oligonucleotide to adipose tissue reduces adiposity in obese mice.Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?Controlled delivery of antisense oligonucleotides: a brief review of current strategies.
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Antisense-based cancer therapeutics: are we there yet?
@ast
Antisense-based cancer therapeutics: are we there yet?
@en
type
label
Antisense-based cancer therapeutics: are we there yet?
@ast
Antisense-based cancer therapeutics: are we there yet?
@en
prefLabel
Antisense-based cancer therapeutics: are we there yet?
@ast
Antisense-based cancer therapeutics: are we there yet?
@en
P2860
P1476
Antisense-based cancer therapeutics: are we there yet?
@en
P2093
Elizabeth Rose Rayburn
P2860
P304
P356
10.1517/14728214.11.2.337
P407
P577
2006-05-01T00:00:00Z